Brief report: Shortened telomere length in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 65, Issue 5, 2013, Pages 1319-1323

  Haque, Sahena ^a,c   Rakieh, Chadi ^b   Marriage, Fiona ^a   Ho, Pauline ^b   Gorodkin, Rachel ^b   Teh, Lee Suan ^c   Snowden, Neil ^d   Day, Philip J R ^a   Bruce, Ian N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c EAST LANCASHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; RO ANTIBODY; ANTINUCLEAR ANTIBODY; GLUCOCORTICOID; SS A ANTIBODIES; SS-A ANTIBODIES;

ADULT; AGING; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POPULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; SMOKING; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TELOMERE HOMEOSTASIS; COMORBIDITY; GENETICS; MIDDLE AGED; OBESITY; RISK FACTOR; TELOMERE; TELOMERE SHORTENING; UNITED KINGDOM;

ADULT; ANTIBODIES, ANTINUCLEAR; ATHEROSCLEROSIS; COMORBIDITY; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OBESITY; RISK FACTORS; SMOKING; TELOMERE; TELOMERE SHORTENING;

MLCS; MLOWN;

EID: 84876557900     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37895     Document Type: Article

References (19)

1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
2. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007; 46: 983-8.
3. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, et al. A human telomeric protein. Science 1995; 270: 1663-7.
4. De Lange T,. Protection of mammalian telomeres. Oncogene 2002; 21: 532-40.
5. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
6. Gladman DD, Ibanez D, Urowitz MB,. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
7. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
8. Cawthon RM,. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009; 37: e21.
9. Aubert G, Lansdorp PM,. Telomeres and aging. Physiol Rev 2008; 88: 557-79.
10. Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, et al. Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28lo T cells in patients with systemic lupus erythematosus. Clin Immunol 2001; 99: 211-21.
11. Wu CH, Hsieh SC, Li KJ, Lu MC, Yu CL,. Premature telomere shortening in polymorphonuclear neutrophils from patients with systemic lupus erythematosus is related to the lupus disease activity. Lupus 2007; 16: 265-72.
12. Beier F, Balabanov S, Amberger CC, Hartmann U, Manger K, Dietz K, et al. Telomere length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus using multi-color flow-FISH. Lupus 2007; 16: 955-62.
13. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662-4.
14. Wolfe F, Michaud K,. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1471-9.
15. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA,. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361: 393-5.
16. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-14.
17. Nie Y, Lau C, Lie A, Chan G, Mok M,. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010; 19: 850-9.
18. Zhou JG, Qing YF, Yang QB, Xie WG, Zhao MC,. Changes in the expression of telomere maintenance genes might play a role in the pathogenesis of systemic lupus erythematosus. Lupus 2011; 20: 820-8.
19. Steer SE, Williams FMK, Kato B, Gardner JP, Norman PJ, Hall MA, et al. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann Rheum Dis 2007; 66: 476-80.